Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603486 | 0.77 | GRM5 (0.56) | GRM5 | |
| SCHEMBL3181785 | 0.70 | CNR2 (0.79) | CNR1 | |
| SCHEMBL21981603 | 0.69 | LMNA (0.49) | GRM5 | |
| SCHEMBL20075545 | 0.68 | LMNA (0.53) | GRM5 | |
| SCHEMBL17675177 | 0.68 | GRM5 (0.64) | GRM5CNR1 | |
| SCHEMBL10959666 | 0.68 | GRM5 (0.57) | GRM5CNR1 | |
| SCHEMBL3595225 | 0.68 | ALDH1A1 (0.49) | GRM5 | |
| SCHEMBL3172028 | 0.67 | CNR1 (0.78) | CNR1 | |
| SCHEMBL3603672 | 0.67 | GRM5 (0.66) | GRM5CNR1 | |
| SCHEMBL10140846 | 0.66 | GRM5 (0.56) | GRM5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293916-B2 | Diazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100048569-A1 | DIAZOLE DERIVATIVES | BUETTELMANN BERND | 2010-02-25 | — | — | US | disclosed |
| EP-1756086-B1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| EP-1756086-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20060030559-A1 | Diazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2005118568-A1 | PYRIDIN-4-YL-ETHYNYL-IMIDAZOLES AND PYRAZOLES AS MGLU5 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048569-A1 | DIAZOLE DERIVATIVES | GRM1, GRM2, GRIN2B | GRM5 14/4885CNR1 106/4885 |
| US-20060030559-A1 | Diazole derivatives | GRM1, GRM2, GRIN2B | GRM5 14/4885CNR1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.